At the time of writing, Relmada Therapeutics Inc [RLMD] stock is trading at $4.27, down -1.16%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The RLMD shares have gain 8.10% over the last week, with a monthly amount glided 93.21%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Relmada Therapeutics Inc [NASDAQ: RLMD] stock has seen the most recent analyst activity on November 19, 2025, when Mizuho upgraded its rating to an Outperform but kept the price target unchanged to $10 for it. Previously, Mizuho downgraded its rating to Neutral on December 05, 2024, and dropped its price target to $1. On September 17, 2024, upgrade upgraded it’s rating to Buy and revised its price target to $13 on the stock. Goldman downgraded its rating to a Sell and decreased its price target to $2 on June 05, 2024. Truist downgraded its rating to a Hold and reduced its price target to $10 on October 14, 2022. Guggenheim downgraded its rating to Neutral for this stock on October 14, 2022. In a note dated October 14, 2022, Goldman downgraded a Neutral rating on this stock and revised its target price from $81 to $8.
For the past year, the stock price of Relmada Therapeutics Inc fluctuated between $0.24 and $5.12. Currently, Wall Street analysts expect the stock to reach $5.67 within the next 12 months. Relmada Therapeutics Inc [NASDAQ: RLMD] shares were valued at $4.27 at the most recent close of the market. An investor can expect a potential return of 32.79% based on the average RLMD price forecast.
Analyzing the RLMD fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -3.21, Equity is -2.23 and Total Capital is -4.41.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.93 points at the first support level, and at 3.59 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.49, and for the 2nd resistance point, it is at 4.71.
Ratios To Look Out For
It is important to note that Relmada Therapeutics Inc [NASDAQ:RLMD] has a current ratio of 2.86. In addition, the Quick Ratio stands at 2.86 and the Cash Ratio stands at 0.26.
Transactions by insiders
Recent insider trading involved Shenouda Maged, Chief Financial Officer, that happened on Nov 05 ’25 when 0.5 million shares were purchased. CAO and COO, Ence Chuck completed a deal on Nov 05 ’25 to buy 0.14 million shares. Meanwhile, Chief Executive Officer TRAVERSA SERGIO bought 0.27 million shares on Nov 05 ’25.
